首页> 外国专利> VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridines for the treatment of diseases caused by persistent angiogenesis

VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridines for the treatment of diseases caused by persistent angiogenesis

机译：VEGFR-2和VEGFR-3抑制性蒽酰胺基吡啶类药物用于治疗持续性血管生成引起的疾病

页面导航

摘要
著录项
相似文献

摘要

VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed, wherein the variables shown in formula (I) are as defined in the specification. These compounds can be used, for example, in tumour or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as for example, stent-induced restenoses, endometriosis, Crohn's disease, Hodgkin's disease, leukaemia, arthritis, such as rheumatoid arthritis, haemangioma, angiofibroma, eye disease, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejection and glomerulopathy, fibrotic diseases, such as liver cirrhosis, mesangial cell proliferative diseases, artherosclerosis, injuries to nervous tissue and inhibition of the reocclusion of vessels after balloon catheter treatment, in vessel prosthetics, or after the application of mechanical devices to hold open vessels, such as for example, stents, as immune suppressants, as a support for scar-free wound healing, age spots and contact dermatitis. Said compounds may also be used as VEGFR-3 inhibitors in lymphangiogenesis.

机译：公开了式（I）的VEGFR-2和VEGFR-3抑制性蒽酰胺基吡啶酰胺，其生产和用作治疗由持续性血管生成引起的疾病的药物以及用于生产所述化合物的中间体，其中式（I）所示的变量如规范中所定义。这些化合物可用于例如肿瘤或转移性生长，牛皮癣，卡波西氏肉瘤，再狭窄，例如支架诱导的再狭窄，子宫内膜异位，克罗恩氏病，霍奇金氏病，白血病，关节炎，例如类风湿性关节炎，血管瘤，血管纤维瘤，眼疾，例如糖尿病性视网膜病，新生血管性青光眼，肾病，例如肾小球肾炎，糖尿病性肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥和肾小球病，纤维化疾病，例如肝硬化，肾小球膜细胞增生病，，在球囊导管治疗后，在血管修复术中或应用机械装置固定开放血管（例如支架）作为免疫抑制剂作为疤痕的支持物后，对神经组织的伤害以及对血管再闭塞的抑制作用免费伤口愈合，老年斑和接触性皮炎。所述化合物还可以在淋巴管生成中用作VEGFR-3抑制剂。

著录项

公开/公告号NZ537291A

专利类型
公开/公告日2007-02-23

原文格式PDF
申请/专利权人 SCHERING AKTIENGESELLSCHAFT;
展开▼

申请/专利号NZ20030537291
发明设计人 MENRAD ANDREAS;HUTH ANDREAS;HESS-STUMP HOLGER;THIERAUCH KARL-HEINZ;KRUGER MARTIN;HABEREY MARTIN;ZORN LUDWIG;INCE STUART;
展开▼

申请日2003-07-22
分类号C07D213/74;A61K31/44;A61P19/00;A61P35/00;C07D213/61;C07D213/73;C07D213/75;C07D401/04;C07D401/12;C07D401/14;C07D409/12;C07D413/04;C07D413/14;C07D417/04;C07D417/10;
国家 NZ
入库时间 2022-08-21 20:56:45

相似文献

专利
外文文献
中文文献